Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$21.9M
8M shares
52-week range
$2.62 – $16.25
-0% from low
Exchange
NASDAQ
ADRC
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
www.radiopharmtheranostics.comNo one on the platform currently holds RADX.
No tracked institution reports a position in RADX as of their last filing.
No one on the platform has traded RADX yet.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $3M | +7.3% | $-4.73 | $-9.43–$-0.03 | — | 1 |
| 2028 | $4M | +42.7% | $-5.91 | $-5.91–$-5.91 | — | 1 |
| 2029 | $84M | +2165.2% | $-0.62 | $-0.62–$-0.62 | — | 1 |
| 2030 | $164M | +96.0% | $2.30 | $2.30–$2.30 | 1.1× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 0 of the last 3 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-02-27 | $-1.51 | $-2.25 | -49.0% |
| 2025-08-29 | $-1.58 | $-1.78 | -12.6% |
| 2025-02-28 | $-1.49 | $-1.91 | -28.0% |
| +4.34% |
| $19M |
| — |
| IBOImpact BioMedical Inc. | $0.43 | -3.80% | $46M | — |
| KTTAPasithea Therapeutics Corp. | $0.49 | -0.22% | $16M | — |
Source: Financial Modeling Prep · peers by sector/industry
$RADX https://www.marketindex.com.au/asx/rad/announcements/notice-of-extraordinary-general-meeting-and-proxy-form-2A1689226
View on StockTwits ↗$RADX what a bunch of fucking scum bags thast run this abortion
View on StockTwits ↗$RADX Isn't the goal to drop below $2 and sell off the company (or RAD 101 for $25 million, lol) to pocket a hefty check for Hopper's management? What about the shareholders? I'd already have a hard time selling my shares below $10, but now we're supposed to imagine selling them at $6 or $7 in the best-case scenario? I find that hard to believe... but there are 30 days left before the shareholder vote (which we're not part of), and in 30 days, of course, we'll be below $2, maybe even $1.50. Our fantasies and desires don't change the downward spiral that's been going on for almost three weeks. 🤬😡🤬I'm going to increase my position to 35000 right now and in stages.
View on StockTwits ↗$RADX This is absolutely disgusting. What game are Paul Hopper and his companies—just like CHM—even playing? Why do they keep suppressing the share prices of companies they hold? What's the end game here? Is it money laundering?
View on StockTwits ↗$RADX Lol, you actually noticed before me what I just realized. I think we're going to lose at least another 10% on our portfolio today, even if the stock goes up 100%. I won't even get my initial investment back. Luckily, the gains from December help put things in perspective, but it's definitely the last time I'll invest in a stock managed by Hopper. I'll find something else to do today. Good luck to everyone.
View on StockTwits ↗Aryeh Sand – Solomon Partners Might be their Adviser $RADX https://solomonpartners.com/people/aryeh-sand/
View on StockTwits ↗$RADX If RAD202 starts producing PRs at 130 mCi and RAD204 gets another PR at 90 mCi or the next dose, I'd personally stop thinking of $350M as an aggressive whole-company valuation. At that point, $500M+ would become a much more credible strategic valuation, even before either therapeutic reaches Phase 2. That's also where a buyer could start worrying that waiting for larger datasets will make RADX substantially more expensive.
View on StockTwits ↗$RADX which will come first ? The efficacy and specificity data of all the assets or the RAD101 deal announcement?
View on StockTwits ↗Lotto Ticket $RADX https://chatgpt.com/s/m_6a7e1ebeee3c81918381263ded770a7d
View on StockTwits ↗$RADX Somebody smart and big soaking up these lotto tickets
View on StockTwits ↗Who are the potential buyers $RADX https://chatgpt.com/s/m_6a7e0f6ea2d881918652706a406b507f
View on StockTwits ↗$RADX per AI Yes. If a serious adviser such as Centerview had actually been retained 6 weeks ago specifically to monetize RAD101, I think the absolute earliest credible deal announcement could be within the next 2–4 weeks. That would put the fastest-case announcement around late August to early/mid-September. A more normal successful process would probably land October–November. The key reason RAD101 could move relatively quickly is that a buyer now has the completed Phase 2b primary data: 93% concordance across 30 evaluable patients, preliminary 86% sensitivity, Fast Track designation, and a Phase 3 supply arrangement already established with Siemens.
View on StockTwits ↗$RADX Big retained advisor working on rad101. Give them another few months and we should be back in green. They didn’t have the data until a few weeks ago. my target is $9+ now given dilution.
View on StockTwits ↗$RADX Why this down from 4.30??? Chapter 11?? Tks
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.